| Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial D Catovsky, S Richards, E Matutes, D Oscier, MJS Dyer, RF Bezares, ... The Lancet 370 (9583), 230-239, 2007 | 932 | 2007 |
| Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study PJ Campbell, LM Scott, G Buck, K Wheatley, CL East, JT Marsden, A Duffy, ... The Lancet 366 (9501), 1945-1953, 2005 | 901 | 2005 |
| Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ... New England Journal of Medicine 372 (17), 1598-1607, 2015 | 810 | 2015 |
| Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma NA Marshall, LE Christie, LR Munro, DJ Culligan, PW Johnston, ... Blood 103 (5), 1755-1762, 2004 | 672 | 2004 |
| In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation PD Kottaridis, DW Milligan, R Chopra, RK Chakraverty, S Chakrabarti, ... Blood, The Journal of the American Society of Hematology 96 (7), 2419-2425, 2000 | 609 | 2000 |
| Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus P Dreger, P Corradini, E Kimby, M Michallet, D Milligan, J Schetelig, ... Leukemia 21 (1), 12-17, 2007 | 523 | 2007 |
| Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial AK Burnett, NH Russell, RK Hills, AE Hunter, L Kjeldsen, J Yin, ... Journal of clinical oncology 31 (27), 3360-3368, 2013 | 470 | 2013 |
| Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. D Bowen, D Culligan, S Jowitt, S Kelsey, G Mufti, D Oscier, J Parker British journal of haematology 120 (2), 2003 | 434 | 2003 |
| High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution S Chakrabarti, S Mackinnon, R Chopra, PD Kottaridis, K Peggs, ... Blood, The Journal of the American Society of Hematology 99 (12), 4357-4363, 2002 | 431 | 2002 |
| Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen R Chakraverty, K Peggs, R Chopra, DW Milligan, PD Kottaridis, ... Blood, The Journal of the American Society of Hematology 99 (3), 1071-1078, 2002 | 402 | 2002 |
| Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation KS Peggs, A Hunter, R Chopra, A Parker, P Mahendra, D Milligan, ... The Lancet 365 (9475), 1934-1941, 2005 | 349 | 2005 |
| Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma E Morris, K Thomson, C Craddock, P Mahendra, D Milligan, G Cook, ... Blood 104 (13), 3865-3871, 2004 | 324 | 2004 |
| Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen JM Davies, R Barnes, D Milligan Clinical medicine 2 (5), 440-443, 2002 | 324 | 2002 |
| Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young YL Chee, DJ Culligan, HG Watson British journal of haematology 114 (4), 878-880, 2001 | 287 | 2001 |
| Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in … S Tauro, C Craddock, K Peggs, G Begum, P Mahendra, G Cook, J Marsh, ... Journal of Clinical Oncology 23 (36), 9387-9393, 2005 | 273 | 2005 |
| Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials K Wheatley, CL Brookes, AJ Howman, AH Goldstone, DW Milligan, ... British journal of haematology 145 (5), 598-605, 2009 | 269 | 2009 |
| The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation DI Marks, R Lush, J Cavenagh, DW Milligan, S Schey, A Parker, FJ Clark, ... Blood, The Journal of the American Society of Hematology 100 (9), 3108-3114, 2002 | 269 | 2002 |
| Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning P Dreger, R Brand, J Hansz, D Milligan, P Corradini, J Finke, GL Deliliers, ... Leukemia 17 (5), 841-848, 2003 | 250 | 2003 |
| guideline Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. D Oscier, C Fegan, P Hillmen, T Illidge, S Johnson, P Maguire, E Matutes, ... British journal of haematology 125 (3), 2004 | 240 | 2004 |
| A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid … WJ Kell, AK Burnett, R Chopra, JAL Yin, RE Clark, A Rohatiner, ... Blood 102 (13), 4277-4283, 2003 | 238 | 2003 |
